ScripBeiGene is expanding its presence in a market worth potentially $1bn or more with the US Food and Drug Administration approval of Tevimbra (tislelizumab-jsgr) for frontline esophageal cancer, where th
Scrip“In the following 10 to 20 years, the next R&D peak in small molecules lies in protein degradation; protein degraders will have a market worth at least $100bn,” Liqiang Fu, co-founder and chief te
Pink SheetThe median review times for US Food and Drug Administration-approved novel agents in 2024 held very close to Prescription Drug User Fee Act goals, highlighting the fundamental predictability of the re
ScripThroughout 2024 and against persistent financial headwinds, novice and returning sole Chinese company sponsors of clinical trials initiated a total of seven new global Phase III programs that included